Hepatic sEH–Nrf2 Axis: A Novel Regulator of Osteoclastogenesis

Study Background and Research Question

Osteoporosis (OP) is a debilitating metabolic bone disorder, marked by reduced bone mass, microarchitectural deterioration, and increased fracture risk. Its pathogenesis centers on an imbalance between osteoclast-mediated bone resorption and osteoblast-driven formation. While the roles of inflammation and redox imbalance in OP are recognized, the precise molecular links between hepatic metabolism and bone remodeling remain incompletely defined. The recent study by Liu et al. (Free Radical Biology and Medicine, 2025) addresses a critical question: Does liver-derived soluble epoxide hydrolase (sEH) regulate osteoclastogenesis through modulation of the Nrf2 signaling pathway, thereby contributing to systemic redox imbalance and osteoporosis?

Key Innovation from the Reference Study

The study's primary innovation lies in elucidating a mechanistic "liver-bone axis," where hepatic sEH modulates bone metabolism remotely. Specifically, the authors demonstrate that increased sEH activity in the liver suppresses the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant signaling pathway in bone tissue, thus enhancing osteoclast differentiation and promoting bone loss. The work identifies the sEH–Nrf2 axis as a direct molecular bridge between hepatic lipid metabolism, systemic redox balance, and skeletal homeostasis—a significant advance over prior models that viewed liver and bone as largely independent metabolic compartments.

Methods and Experimental Design Insights

The investigators employed a multifaceted approach encompassing clinical sample analysis, an ovariectomy (OVX)-induced mouse model of osteoporosis, and in vitro osteoclast differentiation assays. Key methodological highlights include:

• Measurement of plasma 14,15-epoxyeicosatrienoic acid (14,15-EET) and its sEH-catalyzed metabolite 14,15-dihydroxyeicosatrienoic acid (14,15-DHET) in osteoporosis patients and controls.
• Quantification of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) to assess systemic inflammatory status.
• Genetic and pharmacological manipulation of hepatic sEH expression or activity in OVX mice, including liver-specific sEH knockdown and sEH inhibitor administration.
• Transcriptome sequencing of bone tissue to interrogate pathway-level changes, especially within the Nrf2-antioxidant response element (ARE) network.
• Use of in vitro osteoclastogenesis assays—with Nrf2 pathway modulation—to confirm mechanistic links between sEH, EET/DHET balance, and osteoclast differentiation.

Protocol Parameters

• OVX mouse model induction: Bilateral ovariectomy performed to induce postmenopausal osteoporosis phenotypes, with bone loss monitored for several weeks post-surgery.
• sEH inhibitor treatment: Pharmacological sEH inhibitors administered systemically at doses validated by prior redox and enzyme inhibition studies, typically for 2–4 weeks.
• Liver-specific sEH knockdown: Achieved through targeted delivery of shRNA or other gene-silencing methods, with knockdown efficiency verified by hepatic sEH protein and activity assays.
• Osteoclastogenesis assays: Bone marrow-derived macrophages cultured with RANKL and M-CSF; differentiation monitored by TRAP staining and quantification of multinucleated osteoclasts.
• Nrf2 pathway interrogation: Use of pathway-specific agonists/inhibitors and transcriptome profiling to establish causality between sEH activity, Nrf2-ARE signaling, and osteoclastogenic outcomes.

Core Findings and Why They Matter

According to the reference study, osteoporosis patients displayed reduced circulating 14,15-EET, elevated 14,15-DHET, and increased inflammatory cytokines—mirrored in OVX mice with upregulated hepatic sEH. Functional experiments revealed that pharmacological inhibition or genetic knockdown of hepatic sEH:

• Normalized 14,15-EET and 14,15-DHET plasma levels
• Reduced systemic inflammation (lower TNF-α, IL-6, IL-1β)
• Suppressed osteoclast differentiation and mitigated bone loss

Transcriptomic data demonstrated that sEH inhibition activates the Nrf2-ARE pathway in bone, enhancing antioxidant responses and restraining osteoclastogenesis. Direct addition of 14,15-EET to osteoclast cultures recapitulated these protective effects in a strictly Nrf2-dependent manner. Collectively, these results establish that hepatic sEH, through its metabolic regulation of EET/DHET ratios, exerts a remote influence on bone redox status and cell differentiation programs. This mechanistic insight advances our understanding of endocrine and paracrine signaling pathways at the intersection of liver metabolism, inflammation, and skeletal health.

Comparison with Existing Internal Articles

Several recent expert commentaries and workflow articles build on or contextualize the sEH–Nrf2–osteoclastogenesis axis. For example, the article "Redox Regulation and Osteoclastogenesis: Strategic Deployment of BPN-19186" discusses how the fluorinated phenyl urea compound (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) enables reproducible studies of Nrf2 signaling and redox balance in bone biology. Similarly, "New Horizons in sEH–Nrf2 Pathway Research" provides protocol-level insights for dissecting the hepatic sEH–Nrf2 axis using advanced biochemical tools. These resources highlight the translational significance of targeting sEH and Nrf2 in cancer biology research, neuroscience research, and metabolic bone disease models, and underscore the practical value of high-purity, well-characterized small molecule inhibitors in enzyme inhibition studies.

Limitations and Transferability

Despite its comprehensive design, the study's translational scope has boundaries. The OVX mouse model, while representative of postmenopausal osteoporosis, may not fully capture the complexity of human bone and liver interactions across diverse etiologies. Clinical sample sizes were limited, and confounding factors (e.g., comorbid metabolic or inflammatory conditions) could influence sEH–Nrf2 axis activity. Moreover, while sEH inhibition and 14,15-EET supplementation improved redox status and bone outcomes in experimental settings, long-term safety and systemic metabolic consequences of sEH modulation remain to be fully characterized in human populations. The findings, therefore, should be interpreted as providing a mechanistic foundation for future therapeutic exploration rather than immediate clinical translation.

Research Support Resources

For investigators aiming to replicate or extend this work, access to high-purity, research-grade sEH inhibitors is essential. (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186, SKU A8959) from APExBIO is a well-characterized small molecule inhibitor suited for signaling pathway modulation, enzyme inhibition studies, and probing redox regulation in bone or liver models. Researchers are advised to consult product documentation for recommended storage and solubility parameters, and to design experiments that align with the workflow parameters established in recent literature. This approach will help ensure robust, reproducible outcomes in the study of sEH–Nrf2 interactions and their impact on osteoclastogenesis.